Fourth Quarter 2024 Financial Results Total revenue in the fourth quarter of 2024 grew 19% to $21.5 million, compared with $18.0 million in the fourth quarter of 2023. The Company’s revenue growth was ...
Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead ...
Financially stable with $469.5 million in cash, Praxis Precision Medicines can fund operations until 2028. Read why my rating ...
Seizures and dreams are linked among patients with epilepsy, as DRF was associated with seizure frequency and localization.
Epilepsy, a misunderstood neurological disorder, affects millions worldwide, but with proper treatment, individuals can lead ...